Standardized study on the diagnosis and treatment plan of non-alcoholic fatty liver disease treated with the method of clearing phlegm and dampness

Not Applicable

• Conditions: onalcoholic Fatty Liver Disease

• Registration Number: ITMCTR2200006759
• Lead Sponsor: onghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1.Age 18 to 75 years;
2.Patients who meet the above western medical diagnostic criteria and the wet turbidity internal stop certificate;
3.Patients who are willing to sign informed consent.
4.Serum alanine aminotransferase (ALT) = 2 times the upper limit of normal, total bilirubin (TBIL) = 2 times the upper limit of normal

Exclusion Criteria

1. Patients with fatty liver, Reye syndrome fatty liver, ß-lipoprotein deficiency and localized fatty liver caused by chronic heart failure, malnutrition and pregnancy. Patients with fatty liver caused by diabetes, long-term use of hormones, small intestinal bypass surgery, toxic injury to liver cells, chronic febrile diseases such as tuberculosis, ulcerative colitis, and chronic infection after gastrointestinal surgery.
2. Severe fatty liver with ascites, edema, hyponatremia, hypokalemia and other suspected manifestations of liver cirrhosis; hepatitis or cirrhosis caused by virus, drug poisoning, immune diseases and other factors.
3. Other Chinese and Western medicines for the treatment of simple fatty liver have been used after this onset.
4. Patients who have serious primary cardiovascular disease, liver disease, kidney disease, hematological disease, lung disease, or serious diseases that affect their survival, such as tumor or AIDS.
5. Mentally or legally disabled patients.
6. Suspected or indeed have a history of alcohol or drug abuse, or other diseases that reduce the possibility of enrollment or complicate enrollment according to the judgment of the investigator, such as frequent changes in the working environment, which are likely to cause loss to follow-up.
7. Those who are known to be allergic to the components of this medicine.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The liver ultrasound;Fibroscan;

Secondary Outcome Measures

Name	Time	Method
HOMA-IR;Serum biochemistry;WHR;InISI;BMI;curative effect;